Nintedanib Clonmel Healthcare

Nintedanib, the active ingredient in Nintedanib Clonmel Healthcare, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for adults with idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease, conditions characterized by progressive lung scarring.

GNH USA supplies Nintedanib Clonmel Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution, with reliable logistics and traceability.

Nintedanib acts on fibrotic lung disease pathways to limit progression of scarring.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in forced vital capacity. - Systemic sclerosis‑associated interstitial lung disease: improves lung capacity and may delay need for supplemental oxygen. - Progressive fibrosing interstitial lung disease (non‑IPF): helps reduce the rate of lung‑function decline in eligible patients.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Decreased appetite

Serious or Rare Side Effects: - Elevated liver enzymes (ALT/AST) - Severe bleeding events - Gastrointestinal perforation

When prescribing Nintedanib, clinicians should observe several safety measures.

- Liver function monitoring: perform baseline tests and repeat periodically. - Bleeding risk assessment: evaluate concomitant anticoagulant or antiplatelet therapy. - Cardiovascular evaluation: monitor blood pressure and heart function. - Gastrointestinal management: advise patients on hydration and diet to mitigate nausea and diarrhea. - Store at room temperature: keep in original container, protect from moisture and heat.

Nintedanib can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Potent P‑gp inhibitors (e.g., verapamil): may raise exposure. - Anticoagulants and antiplatelet agents: heightened bleeding risk. - High‑dose aspirin or NSAIDs: increased gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug exposure. - Diuretics: risk of dehydration may exacerbate renal side effects.